These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 3138120

  • 1. Effects of cimetidine on interleukin-2 production by peripheral blood lymphocytes in advanced ovarian carcinoma.
    Kikuchi Y, Kizawa I, Oomori K, Iwano I, Kita T, Miyauchi M, Kato K.
    Eur J Cancer Clin Oncol; 1988 Jul; 24(7):1185-90. PubMed ID: 3138120
    [Abstract] [Full Text] [Related]

  • 2. [Effects of cimetidine and PSK on interleukin-2 production by PBL in patients with advanced ovarian carcinoma during the course of chemotherapy].
    Kikuchi Y, Kizawa I, Oomori K, Iwano I, Kita T, Miyauchi M, Kato K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1987 Nov; 39(11):1987-92. PubMed ID: 3501452
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma.
    Kikuchi Y, Oomori K, Kizawa I, Kato K.
    Jpn J Clin Oncol; 1985 Jun; 15(2):377-83. PubMed ID: 3839542
    [Abstract] [Full Text] [Related]

  • 5. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Smith CV, Pecorelli S, Radominska-Pandya A, Cannon MJ, Parham GP.
    Gynecol Obstet Invest; 2001 Jun; 51(4):254-61. PubMed ID: 11408737
    [Abstract] [Full Text] [Related]

  • 6. Augmented natural killer activity in ovarian cancer patients treated with cimetidine.
    Kikuchi Y, Oomori K, Kizawa I, Kato K.
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1037-43. PubMed ID: 3780810
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation of the intracellular expression of interleukin 17 in patients with ovarian cancer].
    Rogala E, Nowicka A, Bednarek W, Barczyński B, Wertel I, Zakrzewski M, Kotarski J.
    Ginekol Pol; 2012 Jun; 83(6):424-8. PubMed ID: 22880461
    [Abstract] [Full Text] [Related]

  • 8. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH.
    Cancer Res; 2001 Jun 15; 61(12):4766-72. PubMed ID: 11406550
    [Abstract] [Full Text] [Related]

  • 9. Increased interleukin-2 receptor expression after mitogen stimulation on CD4- and CD8-positive lymphocytes and decreased interleukin-2 production in HTLV-III antibody-positive symptomatic individuals.
    Creemers PC, O'Shaughnessy M, Boyko WJ.
    Immunology; 1986 Dec 15; 59(4):627-9. PubMed ID: 3100439
    [Abstract] [Full Text] [Related]

  • 10. The effect of cimetidine on PBL from healthy donors and melanoma patients: augmentation of T cell responses to TCGF mitogens and alloantigens and of TCGF production.
    Eisenthal A, Monselise J, Zinger R, Adler A.
    Cancer Immunol Immunother; 1986 Dec 15; 21(2):141-7. PubMed ID: 2936446
    [Abstract] [Full Text] [Related]

  • 11. 1,25-Dihydroxyvitamin-D3 regulation of interleukin-2 and interleukin-2 receptor levels and gene expression in human T cells.
    Jordan SC, Toyoda M, Prehn J, Lemire JM, Sakai R, Adams JS.
    Mol Immunol; 1989 Oct 15; 26(10):979-84. PubMed ID: 2594016
    [Abstract] [Full Text] [Related]

  • 12. Evidence for enhanced interleukin 2 (IL-2) secretion and IL-2 receptor presentation by synovial fluid lymphocytes in rheumatoid arthritis.
    Lemm G, Warnatz H.
    Clin Exp Immunol; 1986 Apr 15; 64(1):71-9. PubMed ID: 3089651
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation.
    Garzetti GG, Ciavattini A, Muzzioli M, Romanini C.
    Cancer; 1999 May 15; 85(10):2226-31. PubMed ID: 10326702
    [Abstract] [Full Text] [Related]

  • 14. [Cell-mediated immune function in NPC patients treated with cimetidine].
    Zeng P, Xiao J, Lei Y.
    Zhonghua Zhong Liu Za Zhi; 1995 May 15; 17(3):223-5. PubMed ID: 7656832
    [Abstract] [Full Text] [Related]

  • 15. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PL.
    Gynecol Oncol; 2001 Jun 15; 81(3):424-32. PubMed ID: 11371133
    [Abstract] [Full Text] [Related]

  • 16. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer.
    Kosmas C, Epenetos AA, Courtenay-Luck NS.
    Cancer; 1994 Jun 15; 73(12):3000-10. PubMed ID: 8199996
    [Abstract] [Full Text] [Related]

  • 17. [Modulation effect of cimetidine on the production of IL-2 and interferon-gamma in patients with gastric cancer].
    Wen QS, Zhang GZ, Kong XT.
    Zhonghua Zhong Liu Za Zhi; 1994 Jul 15; 16(4):299-301. PubMed ID: 7805562
    [Abstract] [Full Text] [Related]

  • 18. Interleukin 2 activity in peripheral blood mononuclear cells of patients with gynecologic malignancies.
    Kikuchi Y, Kita T, Oomori K, Miyauchi M, Iwano I, Kizawa I.
    Med Oncol Tumor Pharmacother; 1988 Jul 15; 5(2):85-90. PubMed ID: 3137397
    [Abstract] [Full Text] [Related]

  • 19. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer.
    Takenoyama M, Yasumoto K, Harada M, Matsuzaki G, Ishida T, Sugimachi K, Nomoto K.
    Immunobiology; 1996 Jul 15; 195(2):140-51. PubMed ID: 8877391
    [Abstract] [Full Text] [Related]

  • 20. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 15; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.